Shared Decision-Making: AFib 2gether Mobile App

University of Massachusetts, Worcester50 enrolled

Overview

Shared Decision-Making: AFib 2gether™ is a research study that focuses on a mobile application developed by Pfizer, Inc with consultation from Dr McManus' called AFib 2gether™. Through this app, patients can determine their risk of stroke due to atrial fibrillation and prioritize questions and concerns for discussion with their cardiology provider.

Study Type

INTERVENTIONAL

Allocation

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Atrial Fibrillation New Onset

Interventions

Afib 2gether TM Mobile ApplicationDEVICE

The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Providers: * Caring for at least 3 patients aged 18 years and older * Have at least 3 patients with International Classification of Diseases tenth revision (ICD-10) diagnostic code consistent with atrial fibrillation (AF) or atrial flutter * Have at least 3 patients with a CHA2DS2-VASc stroke risk score of 2 or more * Have at least 3 patients who are not on anticoagulation * Have at least 3 patients with upcoming appointments within the next 4 months Patients: * Age 18+ * Preferred language is English * Atrial fibrillation diagnosis * Chads vasc score 2 or higher * Not on anticoagulants * No watchman or atrial appendage closure * Had an ambulatory care center (ACC) cardiology appointment in the past 12 months * Future appointment in the next 4 months with the same provider Exclusion Criteria: Providers: * Providers who do not care for at least 3 patients aged 18 years and older * Have patients that do not have an ICD-10 diagnostic code consistent with AF or atrial flutter * Does not have patients with a CHA2DS2-VASc stroke risk score of 2 or more * Their patients are on anticoagulation * Their 3 patients do not have an upcoming visit within the next 4 months Patients: * Under the age of 18; patients * No ICD-10 diagnostic code consistent with AF or atrial flutter * Did not have a visit with a cardiovascular medicine specialist in the previous one year * Patients with a CHA2DS2-VASc score less than 2 * Currently prescribed an anticoagulant * No upcoming cardiology visit in the next 3 months * Has a WATCHMAN device or left atrial appendage closure surgery * On hospice or for whom life expectancy is less than six months and patients * Bleeding episode or fall with injury in the last four weeks * Does not speak English * Prisoner

Locations (1)

UMass Medical School

Worcester, Massachusetts, United States

Outcomes

Primary Outcomes

Patient MARS Scores

Patients evaluated the perceived usefulness of the AFib 2gether mobile application by taking the Mobile App Rating Scale (MARS) questionnaire. This evaluated 3 domains: functionality, aesthetics, and a star-based question. These scores are rated 1-5 with 5 being the highest (best) score.

Time frame: Immediately after visit

Secondary Outcomes

Provider MARS Scores

Providers were asked to navigate the app features and rate their overall opinion of the mobile app by answering questions using the Mobile App Rating Scale (MARS). This scale evaluates 3 domains: functionality, aesthetics, and a star-based rating question. These scores are rated 1-5 with 5 being the highest (best) score.

Time frame: Immediately after visit.

Reason Why the Patient Was Not on AC Prior to Their Appointment

This was an evaluation of why the patient was not on an anticoagulant (AC) prior to their appointment.

Time frame: Immediately after visit

Afib 2gether Accuracy Assessment

The provider was asked to review the patients stroke risk score on the AFib 2gether app and compare to provider clinical assessment for accuracy. The number of accurate scores were recorded. Ten of the original thirteen providers completed this assessment.

Time frame: Immediately after visit.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.